反応式
[CH2:1]1[S:5][C@@H:4]([CH2:6][CH2:7][CH2:8][CH2:9][C:10](NCCCCCC(ON2C(=O)C(S([O-])(=O)=O)CC2=O)=O)=[O:11])[C@H:3]2[NH:32][C:33]([NH:35][C@@H:2]12)=[O:34].[Na+].C(=O)([O-])[O-:38].[Na+].[Na+]>>[OH:38][C:10]([CH2:9][CH2:8][CH2:7][CH2:6][C@H:4]1[C@@H:3]2[C@@H:2]([NH:35][C:33]([NH:32]2)=[O:34])[CH2:1][S:5]1)=[O:11]参加物
3
実験手順
The RA-NAH (10 mg) obtained in the above was dissolved in 0.5 ml of 0.1 M sodium carbonate aqueous solution, subsequently adding 3 mg of sulfo-NHS-LC-biotin (mfd, by Pierce Chemical Company) thereto followed by overnight incubation at 4° C. After overnight dialysis against distilled water thereafter, the dialyzed liquid was lyophilized to obtain the polysaccharide of the present invention in which biotin is bound to the reducing end of NAH (to be referred to as “NAH-biotin” hereinafter) (8 mg).
後処理
- customThe RA-NAH (10 mg) obtained in the
- customat 4° C
- customAfter overnight dialysis
- distillationagainst distilled water
出典と根拠
- ORDレコード
- ord-1b26caafa6a644a48874c7472e44e884
- 出典データセット
- uspto-grants-2015_10
- 特許番号
- US09150902B2
関連ノート
読み込み中…